Chimerix/CMRX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Chimerix

Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.

Ticker

CMRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

Headquarters

Durham, United States

Employees

72

Chimerix Metrics

BasicAdvanced
$87M
Market cap
-
P/E ratio
-$0.93
EPS
1.28
Beta
-
Dividend rate
$87M
1.28
$1.57
$0.88
6.5
8.61
-36.50%
-39.86%
-39.59%
2,113.517
0.498
0.498
-99.88%
-146.48%
-60.78%

What the Analysts think about Chimerix

Analyst Ratings

Majority rating from 7 analysts.
Buy

Chimerix Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$22M
20.44%
Profit margin
0.00%
NaN%

Chimerix Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 13.86%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.21
-$0.27
-$0.20
-$0.25
-
Expected
-$0.24
-$0.23
-$0.24
-$0.22
-$0.24
Surprise
-13.78%
17.98%
-15.20%
13.86%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Chimerix stock?

Chimerix (CMRX) has a market cap of $87M as of June 24, 2024.

What is the P/E ratio for Chimerix stock?

The price to earnings (P/E) ratio for Chimerix (CMRX) stock is 0 as of June 24, 2024.

Does Chimerix stock pay dividends?

No, Chimerix (CMRX) stock does not pay dividends to its shareholders as of June 24, 2024.

When is the next Chimerix dividend payment date?

Chimerix (CMRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Chimerix?

Chimerix (CMRX) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Chimerix stock price target?

The target price for Chimerix (CMRX) stock is $7, which is NaN% below the current price of $. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Chimerix stock

Buy or sell Chimerix stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing